The Risks of Clinical Expression of Alzheimer’s Disease (AD) in People with Biomarkers of Alzheimer's Pathology

Abstract

Background: The widespread availability of biomarkers of Alzheimer’s pathology (BAP) opens new diagnostic considerations for those who have not clinically expressed the disease but who are identified as being at increased risk based on their BAP.